Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lance Larsen

Pain Medicine Fresno, CA Medical Doctor

NPI 1821013962 CMS profile 984787

1270 E Spruce Ave, Fresno, CA 93720

Open in the dashboard

General payments

$34,749

1,019 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lance Larsen of Fresno, CA is reported in the CMS Open Payments database as having received $34,749 across 1,019 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,591 161
2024 General $10,760 295
2023 General $7,919 254
2022 General $6,443 184
2021 General $1,730 81
2020 General $1,012 28
2019 General $1,294 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lance Larsen
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Lance Larsen were reported at $5,591. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Lance Larsen Pain Medicine median Middle half National median
2019 $1,294 $409 $115–$1,311 $163
2020 $1,012 $214 $66–$666 $114
2021 $1,730 $299 $84–$899 $132
2022 $6,443 $335 $103–$1,149 $149
2023 $7,919 $376 $114–$1,228 $160
2024 $10,760 $387 $115–$1,173 $164
2025 $5,591 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Painteq LLC $9,497 212 payments
  2. Boston Scientific Corporation $9,120 356 payments
  3. Nevro Corp. $4,493 112 payments
  4. Abbott Laboratories $3,529 100 payments
  5. BIOTRONIK NRO, Inc. $1,626 61 payments
  6. Globus Medical, Inc. $1,159 31 payments
  7. SPR Therapeutics, Inc $941 18 payments
  8. Nalu Medical, Inc. $912 41 payments
  9. Medtronic, Inc. $891 30 payments
  10. Saluda Medical Americas, Inc. $544 14 payments
  11. Other $2,037 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $31,520 1,001 payments
  2. Consulting Fee $1,700 3 payments
  3. Travel and Lodging $1,215 11 payments
  4. Entertainment $234 1 payment
  5. Education $79 3 payments
Products named General payments · program years 2019–2025
  1. PAINTEQ $9,497 212 payments
  2. Senza Spinal Cord Stimulator $2,490 72 payments
  3. WaveWriter Alpha Prime 16 $2,118 70 payments
  4. PROCLAIM $2,022 74 payments
  5. Omnia $1,473 22 payments
  6. General - Pain Management $1,464 59 payments
  7. SPRINT PNS System $941 18 payments
  8. Nalu Neurostimulation System $912 41 payments
  9. Prospera $832 32 payments
  10. Senza Spinal Cord Stimulator $700 25 payments
  11. Other $9,474 284 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

647

Median for Pain Management: 951

Drug cost

$7,977

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 305 $5,257
Gabapentin Generic 158 $1,375
Duloxetine Hcl Generic 28 $500
Cyclobenzaprine Hcl Generic 68 $247
Pregabalin Generic 21 $243
Ibuprofen Generic 25 $190
Meloxicam Generic 42 $166

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$308,840

Of which drugs: $925

Medicare patients

863

Average age 75

Services billed

8,080

505 women, 358 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 37%
Diabetes 33%
Osteoporosis 25%
Chronic kidney disease 24%
Depression 21%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 78 880 $669
Injection, ropivacaine hydrochloride, 1 mg J2795 Office 74 1,991 $104
Injection, ketorolac tromethamine, per 15 mg J1885 Office 26 141 $81
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 20 1,056 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,019 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record